A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
作者信息
Fukumoto Takeshi, Fujiwara Susumu, Sakaguchi Masanobu, Oka Masahiro, Nishigori Chikako
机构信息
Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA, USA, Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan.
Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan.
出版信息
Eur J Dermatol. 2018 Feb 1;28(1):115-116. doi: 10.1684/ejd.2017.3169.
PMID:29171409
Abstract
摘要
相似文献
1
A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
Eur J Dermatol. 2018 Feb 1;28(1):115-116. doi: 10.1684/ejd.2017.3169.
2
Pegylated interferon-α2b for local control of Langerhans cell sarcoma.
Eur J Dermatol. 2018 Dec 1;28(6):835-836. doi: 10.1684/ejd.2018.3411.
3
Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
Lancet. 2008 Jul 12;372(9633):89-90. doi: 10.1016/S0140-6736(08)61011-9.
4
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Eur J Cancer. 2013 Jan;49(1):166-74. doi: 10.1016/j.ejca.2012.07.018. Epub 2012 Sep 10.
5
Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
J Dermatol. 2016 Oct;43(10):1146-1153. doi: 10.1111/1346-8138.13338.
6
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
J Clin Oncol. 2012 Nov 1;30(31):3810-8. doi: 10.1200/JCO.2011.41.3799. Epub 2012 Sep 24.
7
Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
Tumori. 2012 Mar-Apr;98(2):185-90. doi: 10.1177/030089161209800202.
8
Adjuvant interferon therapy for malignant melanoma: the debate.
Chin J Cancer. 2010 Nov;29(11):907-13. doi: 10.5732/cjc.010.10169.
9
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Cancer. 2006 Jun 1;106(11):2445-51. doi: 10.1002/cncr.21909.
10
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).
Cancer Immunol Immunother. 2013 Jul;62(7):1223-33. doi: 10.1007/s00262-013-1428-4. Epub 2013 Apr 27.
引用本文的文献
1
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.
Front Immunol. 2019 May 7;10:990. doi: 10.3389/fimmu.2019.00990. eCollection 2019.
Zotero 插件